Teleflex (TFX) Aktievy
Teleflex Incorporated designar, utvecklar, tillverkar och levererar medicintekniska produkter för engångsbruk för vanliga diagnostiska och terapeutiska procedurer inom intensivvård och kirurgiska tillämpningar i USA, Europa, Mellanöstern, Afrika, Asien och Stillahavsområdet samt internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 3/6 |
| Framtida tillväxt | 3/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 1/6 |
| Utdelningar | 2/6 |
TFX Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Teleflex Incorporated Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$132.75 |
| 52 veckors högsta | US$139.67 |
| 52 veckors lägsta | US$100.18 |
| Beta | 0.81 |
| 1 månads förändring | -4.37% |
| 3 månaders förändring | 14.98% |
| 1 års förändring | 9.91% |
| 3 års förändring | -42.87% |
| 5 års förändring | -66.99% |
| Förändring sedan börsintroduktionen | 35,334.77% |
Senaste nyheter och uppdateringar
Recent updates
TFX: Business Separation And Portfolio Focus Will Reshape Future Earnings Profile
Analysts have reduced their fair value estimate for Teleflex to $147 from $155, citing updated assumptions for revenue growth, profit margins, and future P/E multiples following recent upgrades and price target increases from several research firms. Analyst Commentary Recent research has skewed more optimistic on Teleflex, with several bullish analysts updating their views following the company’s Q4 results, guidance, and plans for a major business transformation.
TFX: Business Separation Execution And Activist Pressure Will Constrain Forward Upside
Teleflex's analyst price target is now framed slightly higher, moving from about $115 to roughly $117. Analysts are factoring in updated assumptions on fair value, discount rate, revenue growth, profit margins, and future P/E following recent upgrades and price target increases tied to the company's ongoing business separation and portfolio optimization efforts.TFX: Business Separation And Activist Pressure Will Shape Balanced Forward Outlook
Analysts have raised their average price target for Teleflex to $125 from $115. They cite the company’s ongoing business separation, portfolio optimization, and preparation for future value-creating opportunities as key reasons for the change.TFX: Business Separation And Leadership Changes Will Shape Balanced Forward Outlook
Narrative update Analysts have raised the Teleflex price target by $10, to $125 from $115, citing the company's business separation efforts, portfolio optimization, and positioning for future value creating opportunities following recent results and guidance. Analyst Commentary Recent research highlights a mixed backdrop for Teleflex, with some firms adjusting targets higher while others stay guarded.TFX: Business Separation And Portfolio Optimization Will Drive Future Earnings Quality
Narrative Update on Teleflex The analyst price target on Teleflex has shifted toward $125, with analysts pointing to the company’s ongoing business separation, portfolio optimization, and positioning for future value-creating opportunities as key factors behind the revised outlook. Analyst Commentary Bullish analysts are pointing to recent price target moves and rating actions as signals of growing confidence in Teleflex’s ability to execute on its transformation plan and to support higher valuation levels over time.
TFX: Higher Margin Assumptions And CEO Transition Will Shape Bullish Outlook
Narrative Update on Teleflex The updated analyst price target on Teleflex has shifted by $23, with analysts citing refreshed views on long term profit margins and a slightly higher assumed future P/E multiple as key drivers behind the change. Analyst Commentary Recent Street research on Teleflex reflects a mix of optimism about the company’s long term potential and caution around valuation and execution, which helps explain the updated price target.TFX: CEO Transition And Refined Assumptions Will Shape Bullish Future Outlook
Analysts have adjusted their price targets on Teleflex by aligning fair value estimates to about $129.25. This reflects updated views on the discount rate, revenue growth, profit margin and future P/E assumptions highlighted in recent research, including a Wells Fargo target cut and a Needham upgrade.TFX: Leadership Transition And Softer Demand Will Shape Steady Forward Outlook
Analysts kept their Teleflex fair value estimate steady at US$115.00, as slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E led them to view the prior price target as still appropriate. What's in the News Board member Stuart Randle has been appointed Interim President and CEO effective January 8, 2026, replacing Liam Kelly.TFX: Softer Demand And Leadership Change Will Shape Balanced Outlook
Analysts have reduced their price target on Teleflex from US$120.00 to US$115.00, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. What's in the News Teleflex issued preliminary 2025 revenue guidance of US$3.270b to US$3.278b, below its prior outlook of US$3.305b to US$3.320b, citing softer demand for intra aortic balloon pumps and catheters in the U.S. and Asia, delays in OEM purchase orders, and lower order volumes across parts of its portfolio (Key Developments).TFX: Margin Expansion Will Drive Stronger Earnings Despite Revenue Headwinds
Analysts have raised their price target on Teleflex from 152.80 dollars to 155.00 dollars, reflecting expectations for meaningfully higher profit margins that more than offset slightly slower projected revenue growth and a lower future earnings multiple. What's in the News Teleflex narrowed its full year 2025 GAAP revenue growth outlook to 9.10% to 9.60%, and now expects revenue between 3,325 million dollars and 3,340 million dollars.Teleflex: Selling, But How Much?
Summary Teleflex Incorporated rebounded from lows after announcing a $2.03B divestiture of Acute Care, Interventional Urology, and OEM businesses. TFX will use $1B of net proceeds for share buybacks, reducing pro forma net debt to $1.5B, but revenue impact remains ambiguous. Shares now trade at 10x adjusted earnings, with market reaction positive despite uncertainty around divested revenue figures. I maintain a cautious long position, closely monitoring Q4 results to clarify divestment implications and future margin trajectory. Read the full article on Seeking AlphaTFX: Diabetes Trial And Goodwill Charge Will Shape Balanced Future Outlook
Analysts have modestly adjusted their price target on Teleflex, keeping fair value steady at approximately $124.14 per share while refining assumptions for a slightly lower discount rate and marginally improved long term valuation metrics. This reflects incremental confidence in the company’s earnings durability.TFX: Future Diabetes Trial Progress Will Drive Upside Despite Margin Pressures
Teleflex's analyst price target has been revised downward by $3.57 to $124.14. Analysts cite modest reductions in expected profit margins and growth as driving factors for the update.Teleflex (NYSE:TFX) Has Announced A Dividend Of $0.34
Teleflex Incorporated ( NYSE:TFX ) has announced that it will pay a dividend of $0.34 per share on the 15th of...TFX: Future Advances In Diabetes Trials And Asian Market Expansion Will Drive Upside
Analysts have revised their price target for Teleflex downward from $132.63 to $127.71. They cite higher discount rates and softer revenue growth projections, despite improved profit margins and a lower expected future price-to-earnings ratio.Teleflex Incorporated (NYSE:TFX) Not Lagging Market On Growth Or Pricing
Teleflex Incorporated's ( NYSE:TFX ) price-to-earnings (or "P/E") ratio of 29.5x might make it look like a strong sell...These 4 Measures Indicate That Teleflex (NYSE:TFX) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Acquisitions And Asian Expansion Will Broaden Healthcare Horizons
Despite a near-term upside from strong Q2 results, Teleflex’s consensus price target has been revised down to $132.62 due to persistently modest organic growth and muted EPS increases, with valuation already reflecting current expectations despite anticipated second-half acceleration. Analyst Commentary Strong Q2 results provided near-term upside surprise.Results: Teleflex Incorporated Exceeded Expectations And The Consensus Has Updated Its Estimates
Last week saw the newest quarterly earnings release from Teleflex Incorporated ( NYSE:TFX ), an important milestone in...Teleflex (NYSE:TFX) Has Announced A Dividend Of $0.34
Teleflex Incorporated ( NYSE:TFX ) has announced that it will pay a dividend of $0.34 per share on the 15th of...Teleflex Incorporated (NYSE:TFX) Not Lagging Market On Growth Or Pricing
With a price-to-earnings (or "P/E") ratio of 35.1x Teleflex Incorporated ( NYSE:TFX ) may be sending very bearish...Investors Met With Slowing Returns on Capital At Teleflex (NYSE:TFX)
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Amongst...Teleflex's Bold Transformation: Why I'm Skeptical On Value Creation
Summary Teleflex's management announced a significant acquisition and business split, but the market reacted negatively, dropping the shares over 20%. Fourth quarter earnings and 2025 guidance show weak revenue growth and margin leverage, with potential risks from tariffs and poor execution in key areas. The acquisition of BIOTRONIK's vascular intervention business is risky; it expands Teleflex's vascular intervention business, but the end markets aren't growing that fast and the company is a smaller player. Splitting the business into RemainCo and NewCo makes strategic sense, but NewCo may struggle with growth and margin leverage as a smaller entity. Even with conservative modeling and valuation assumptions, Teleflex stock looks undervalued by more than 20%, but it's tough to recommend a stock where I have serious doubts about execution and strategy. Read the full article on Seeking AlphaTeleflex Incorporated: Compelling Only On One Metric
Summary Teleflex Incorporated, a diversified medical device company, saw a 17% stock drop after Q3 results in late October. The stock now trades at under 13.5 EPS (non-GAAP) and at the equity's lowest price-to-sales ratio in a decade. Have the shares fallen into the 'buy zone'? An analysis of Teleflex Incorporated follows in the paragraphs below. Read the full article on Seeking AlphaAktieägarnas avkastning
| TFX | US Medical Equipment | US Marknad | |
|---|---|---|---|
| 7D | 2.3% | 4.4% | 1.0% |
| 1Y | 9.9% | -17.9% | 28.7% |
Avkastning vs industri: TFX översteg US Medical Equipment branschen som gav -17.9 % under det senaste året.
Avkastning vs Marknaden: TFX presterade sämre än US marknaden som gav 28.7 % under det senaste året.
Prisvolatilitet
| TFX volatility | |
|---|---|
| TFX Average Weekly Movement | 6.2% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: TFX har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: TFX s veckovolatilitet ( 6% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1943 | 15,500 | Stu Randle | www.teleflex.com |
Teleflex Incorporated designar, utvecklar, tillverkar och levererar medicintekniska produkter för engångsbruk för vanliga diagnostiska och terapeutiska procedurer inom intensivvård och kirurgiska tillämpningar i USA, Europa, Mellanöstern, Afrika, Asien och Stillahavsområdet samt internationellt. Företaget erbjuder produkter inom kärl- och akutmedicin som omfattar Arrow-märkta katetrar, system för navigering av katetrar och positionering av spetsar samt system för intraosseös benaccess för administrering av intravenösa behandlingar, mätning av blodtryck och insamling av blodprover; system för intraosseös access som består av EZ-IO system för intraosseös kärlaccess och Arrow FAST1 system för sternal intraosseös infusion; samt hemostatiska produkter, inklusive externa hemostater och traumaprodukter under varumärket QuikClot. Företaget tillhandahåller också interventionsprodukter, inklusive olika kranskärlskatetrar, strukturella hjärtstödjande enheter och plattformar för perifera interventionsprodukter; GuideLiner-, Turnpike- och TrapLiner-katetrar; MANTA kärlförslutningsanordningar och Arrow OnControl drivna benbiopsisystem; samt medicintekniska produkter för kranskärl och periferi, såsom läkemedelsbelagda ballonger, stentar och ballongkatetrar.
Teleflex Incorporated Sammanfattning av grunderna
| TFX grundläggande statistik | |
|---|---|
| Börsvärde | US$5.84b |
| Vinst(TTM) | US$1.36m |
| Intäkter(TTM) | US$2.13b |
Är TFX övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| TFX resultaträkning (TTM) | |
|---|---|
| Intäkter | US$2.13b |
| Kostnad för intäkter | US$949.97m |
| Bruttovinst | US$1.18b |
| Övriga kostnader | US$1.18b |
| Intäkter | US$1.36m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 0.031 |
| Bruttomarginal | 55.33% |
| Nettovinstmarginal | 0.064% |
| Skuld/egenkapitalförhållande | 86.6% |
Hur har TFX utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
Ger TFX en tillförlitlig utdelning?
Se TFX utdelningshistorik och jämförelsetal| Teleflex datum för utdelning | |
|---|---|
| Ex utdelningsdag | May 22 2026 |
| Utbetalningsdag för utdelning | Jun 30 2026 |
| Dagar till Ex-utdelning | 1 day |
| Dagar till utdelningsdag | 38 days |
Ger TFX en tillförlitlig utdelning?
Se TFX utdelningshistorik och jämförelsetalFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/22 08:11 |
| Aktiekurs vid dagens slut | 2026/05/22 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Teleflex Incorporated bevakas av 26 analytiker. 11 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Matthew Taylor | Barclays |
| Travis Steed | BofA Global Research |
| Travis Steed | BofA Global Research |